The ganglioside GD2 induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the GD3 synthase

Glycobiology

Volumn 22, Issue 6, 2012, Pages 806-816

  Cazet, Aurélie ^a,b   Bobowski, Marie ^a,b   Rombouts, Yoann ^a,b   Lefebvre, Jonathan ^a,c   Steenackers, Agata ^a,b   Popa, Iuliana ^d   Guérardel, Yann ^a,b   Le Bourhis, Xuefen ^a,e   Tulasne, David ^a,c   Delannoy, Philippe ^a,b  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^c INSTITUT DE BIOLOGIE DE LILLE   (France)

^d UNIV PARIS SUD   (France)

^e INSERM   (France)

Author keywords

Breast cancer; C Met; Cell proliferation; GD2 ganglioside; GD3 synthase

Indexed keywords

GANGLIOSIDE GD2; GANGLIOSIDE GD3; GLYCOSPHINGOLIPID; GROWTH FACTOR; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; ALPHA N ACETYLNEURAMINATE ALPHA 2,8 SIALYLTRANSFERASE; ALPHA-N-ACETYLNEURAMINATE ALPHA-2,8-SIALYLTRANSFERASE; GANGLIOSIDE; GANGLIOSIDE, GD2; SIALYLTRANSFERASE;

ARTICLE; ASSAY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; CELL MEMBRANE; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SERUM; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL CULTURE;

MUS;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL MEMBRANE; CELL PROLIFERATION; GANGLIOSIDES; HUMANS; MASS SPECTROMETRY; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIALYLTRANSFERASES; TUMOR CELLS, CULTURED;

EID: 84860355482     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cws049     Document Type: Article

References (50)

1. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R, Furukawa K. 2005. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: Roles of anoikis. J Biol Chem. 280: 29828-29836.
2. Ariga T, McDonald MP, Yu RK. 2008. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease. J Lipid Res. 49: 1157-1175.
3. Birklé S, Zeng G, Gao L, Yu RK, Aubry J. 2003. Role of tumor-associated gangliosides in cancer progression. Biochimie. 85: 455-463.
4. Cazet A, Groux-Degroote S, Teylaert B, Kwon KM, Lehoux S, Slomianny C, Kim CH, Le Bourhis X, Delannoy P. 2009. GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. Biol Chem. 390: 601-609.
5. Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, Tutt A, Tulasne D, Le Bourhis X, Delannoy P. 2010. GD3 synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res. 8: 1526-1535.
6. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO. 2004. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res. 10: 4717-4723.
7. Cheresh DA, Klier FG. 1986. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol. 102: 1887-1897.
8. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. 1986. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 102: 688-696.
9. Ciucanu I, Kerek F. 1984. A simple and rapid method for the permethylation of carbohydrates. Carbohydr Res. 131: 209-217.
10. Dubois C, Manuguerra JC, Hauttecoeur B, Maze J. 1990. Monoclonal antibody A2B5, which detects cell surface antigens, binds to ganglioside GT3 (II3 (NeuAc)3LacCer) and to its 9-O-acetylated derivative. J Biol Chem. 265: 2797-2803.
11. Fukumoto S, Mutoh T, Hasegawa T, Miyazaki H, Okada M, Goto G, Furukawa K, Urano T. 2000. GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation. J Biol Chem. 275: 5832-5838.
12. Furukawa K, Hamamura K, Aixinjueluo W, Furukawa K. 2006. Biosignals modulated by tumor-associated carbohydrate antigens: Novel targets for cancer therapy. Ann NY Acad Sci. 1086: 185-198.
13. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, et al. 2009. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA. 106: 12909-12914.
14. Hakomori SI. 2002. Inaugural article: The glycosynapse. Proc Natl Acad Sci USA. 99: 225-232.
15. Hyuga S, Kawasaki N, Hyuga M, Ohta M, Shibayama R, Kawanishi T, Yamagata S, Yamagata T, Hayakawa T. 2001. Ganglioside GD1a inhibits HGF-induced motility and scattering of cancer cells through suppression of tyrosine phosphorylation of c-Met. Int J Cancer. 94: 328-334.
16. Kaucic K, Liu Y, Ladisch S. 2006. Modulation of growth factor signaling by gangliosides: Positive or negative? Methods Enzymol. 417: 168-185.
17. Kawashima N, Yoon SJ, Itoh K, Nakayama K. 2009. Tyrosine kinase activity of epidermal growth factor receptor is regulated by GM3 binding through carbohydrate to carbohydrate interactions. J Biol Chem. 284: 6147-6155.
18. Ko K, Furukawa K, Takahashi T, Urano T, Sanai Y, Nagino M, Nimura Y, Furukawa K. 2006. Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. Oncogene. 25: 6924-6935.
19. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2DDCT method. Methods. 25: 402-408.
20. Lo AS, Ma Q, Liu DL, Junghans RP. 2010. Anti-GD3 chimeric sFv-CD28/T-cell receptor ζ designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res. 16: 2769-2780.
21. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S. 1996. Gangliosides expressed in human breast cancer. Cancer Res. 56: 5165-5171.
22. Miljan EA, Bremer EG. 2002. Regulation of growth factor receptors by gangliosides. Sci STKE. 160: re15.
23. Navid F, Santana VM, Barfield RC. 2010. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets. 10: 200-209.
24. Park SY, Yoon SJ, Freire-de-Lima L, Kim JH, Hakomori SI. 2009. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells. Carbohydr Res. 344: 1479-1486.
25. Peschard P, Park M. 2007. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene. 26: 1276-1285.
26. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, et al. 2009. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA. 106: 12903-12908.
27. Portoukalian J, Bouchon B. 1986. Hydrolysis of all gangliosides, including GM1 and GM2, on thin-layer plates by Vibrio cholerae neuraminidase. J Chromatogr. 380: 386-392.
28. Portoukalian J, David MJ, Gain P, Richard M. 1993. Shedding of GD2 ganglioside in patients with retinoblastoma. Int J Cancer. 53: 948-951.
29. Portoukalian J, Zwingelstein G, Doré JF. 1979. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem. 94: 19-23.
30. Prokazova NV, Bergelson LD. 1994. Gangliosides and atherosclerosis. Lipids. 29: 1-5.
31. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. 1982. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med. 155: 1133-1147.
32. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. 2003. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 9: 5214-5220.
33. Ruckhäberle E, Karn T, Rody A, Hanker L, Gätje R, Metzler D, Holtrich U, Kaufmann M. 2009. Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol. 135: 1005-1013.
34. Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, et al. 2008. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 112: 41-52.
35. Schnaar RL. 1994. Isolation of glycosphingolipids. Methods Enzymol. 230: 348-370.
36. Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, Smyth FE, Lee FT, Cebon J, Davis ID, Hopkins W, et al. 2005. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun. 22: 3-15.
37. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100: 8418-8423.
38. Svennerholm L. 1963. Chromatographic separation of brain gangliosides. J Neurochem. 10: 613-623.
39. Tettamanti G. 2004. Ganglioside/glycosphingolipid turnover: New concepts. Glycoconj J. 20: 301-317.
40. Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. 2007. Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J Biol Chem. 282: 8123-8133.
41. Todeschini AR, Dos Santos JN, Handa K, Hakomori SI. 2008. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci USA. 105: 1925-1930.
42. Todeschini AR, Hakomori SI. 2008. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta. 1780: 421-433.
43. Wang XQ, Sun P, Paller AS. 2001. Inhibition of integrin-linked kinase/protein kinase B/Akt signaling: Mechanism for ganglioside-induced apoptosis. J Biol Chem. 276: 44504-44511.
44. Wang XQ, Sun P, Paller AS. 2002. Ganglioside modulation regulates epithelial cell adhesion and spreading via ganglioside-specific effects on signaling. J Biol Chem. 277: 40410-40419.
45. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, Proia RL. 1999. A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci USA. 96: 9142-9147.
46. Yoon SJ, Nakayama K, Hikita T, Handa K, Hakomori SI. 2006. Epidermal growth factor receptor tyrosine kinase is modulated by GM3 interaction with N-linked GlcNAc termini of the receptor. Proc Natl Acad Sci USA. 103: 18987-18991.
47. Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. 2001. Ganglioside G(D2) in small cell lung cancer cell lines: Enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 61: 4244-4252.
48. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. 2010. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 363: 1324-1334.
49. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK. 2009. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 15: 5852-5860.
50. Zeng G, Yu RK. 2008. Cloning and transcriptional regulation of genes responsible for synthesis of gangliosides. Curr Drug Targets. 9: 317-324.